Alaunos Therapeutics, Inc.
TCRT
$2.65
-$0.03-1.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.00K | -- | 4.00K | 1.00K | 1.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.00K | -- | 4.00K | 1.00K | 1.00K |
| Cost of Revenue | -86.00K | 143.00K | 180.00K | 126.00K | 933.00K |
| Gross Profit | 90.00K | -143.00K | -176.00K | -125.00K | -932.00K |
| SG&A Expenses | 845.00K | 1.01M | 990.00K | 1.62M | 2.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 759.00K | 1.15M | 1.17M | 1.74M | 3.36M |
| Operating Income | -755.00K | -1.15M | -1.17M | -1.74M | -3.36M |
| Income Before Tax | -742.00K | -1.13M | -1.13M | -1.68M | -7.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -742.00K | -1.13M | -1.13M | -1.68M | -7.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -742.00K | -1.13M | -1.13M | -1.68M | -7.84M |
| EBIT | -755.00K | -1.15M | -1.17M | -1.74M | -3.36M |
| EBITDA | -754.50K | -1.15M | -1.17M | -1.74M | -3.12M |
| EPS Basic | -0.46 | -0.70 | -0.71 | -1.05 | -4.90 |
| Normalized Basic EPS | -0.29 | -0.44 | -0.44 | -0.66 | -1.27 |
| EPS Diluted | -0.46 | -0.70 | -0.71 | -1.05 | -4.90 |
| Normalized Diluted EPS | -0.29 | -0.44 | -0.44 | -0.66 | -1.27 |
| Average Basic Shares Outstanding | 1.60M | 1.60M | 1.60M | 1.60M | 1.60M |
| Average Diluted Shares Outstanding | 1.60M | 1.60M | 1.60M | 1.60M | 1.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |